A new study has found that a combination of two drugs could enhance the immune system to treat one of the most common types of cancer in the world, bowel cancer. Also known as colorectal cancer, despite its widespread presence, the treatment options for this condition are limited. What the study specifically found was that this procedure could shrink the tumours caused by this condition by around 60%.
What Are The Drugs Involved
The trial involved the use of two immunotherapy drugs, botancilimab and balstilumab. It is a monoclonal antibody that works to stimulate the body's immune system to attack cancer. The study is a rather significant find, as it’s the first time that a consistent and durable response to immunotherapy has been reported in patients with solid MSS mCRC tumours.
The study was divided into several phases for more than 6 months. In the US trial, around around 101 patients with microsatile stable metastatic colorectal (MSS-mCRC) tumours showed a decrease . Around 61% of the patients experienced tumour shrinkage or stabilization after combined treatment with votancilumab and balstilumab. When it comes to downsides, diarrhea and fatigue were found to be the most common side effects or side effects of this drug.
These results are interesting and open to exploration. To date, immunotherapy has not been effective in patients with CNS-mCRC tumors. This study demonstrates the potential of the combination of botenlimab and balstilimab in the treatment of CNS mCRC, providing new hope for people diagnosed with colon cancer.
What Could This Mean For Bowel Cancer Treatment In The Future
The study is currently in the final stages of clinical trials, and the US Food and Drug Administration (FDA) hopes to quickly gain approval for its use because of the importance of this area that affects many people. The efficiency shown demonstrates the potential of botansilimab to contribute to broad antitumor immunity.
All in all, the combination of botensilimab and balstilimab represents a promising new direction in the treatment of colorectal cancer. This breakthrough could improve conditions for many patients worldwide and lights a new hope in the fight against this common disease. The results of this study show the effectiveness of immunotherapy in this field and how its potential to transform cancer treatment can only grow in the years to come.
Credit: iStock
For the first time, starting July 1, people in the US will be able to access GLP-1 drugs for weight loss through a new pilot program offered by the federal health insurance program Medicare.
Until now, Medicare covered GLP-1 medications such as Ozempic only for certain conditions like diabetes, but not for weight loss.
The new 18-month Medicare GLP-1 Bridge Program, which will run till the end of 2027, aims to make these high-cost weight-loss medications more accessible to eligible beneficiaries.
According to a KFF analysis of 2023 Part D enrollment data, an estimated 3.8 million Medicare beneficiaries could qualify for the program.
More than 70 per cent of adults in the United States are considered to have obesity or screen as overweight. Studies have proven that GLP-1s are an effective tool in weight reduction, as well as improving other markers of good health, such as blood pressure, lipid profiles, and blood sugar levels.
Eligible beneficiaries will be able to access the following GLP-1 weight-loss medications:
The medications will be covered only when prescribed for weight management and when beneficiaries meet the program's medical eligibility criteria.
The program is available only to certain members of Medicare Part D prescription drug plans who want to lose excess weight and maintain weight loss.
Although the program operates outside standard Medicare Part D coverage, beneficiaries can participate only if they are enrolled in:
People enrolled in certain less common Medicare plans, including the Program of All-inclusive Care for the Elderly (PACE), may also qualify if they also have a stand-alone Part D plan, Washington Post reported.
According to the Centers for Medicare & Medicaid Services (CMS), most of Medicare's approximately 57 million Part D enrollees are in eligible plans.
However, coverage is not automatic. Providers and pharmacists will identify eligible patients, submit the required forms and obtain prior authorization before treatment can begin. Claims, prior authorization requests and pharmacy payments will be handled by Humana, while Part D plans will not be involved in the process.
Eligible beneficiaries will pay a $50 monthly copay for the covered medications.
However, because the program operates outside Medicare Part D coverage:
The pilot program is temporary and is scheduled to end in December 2027, unless it is extended.
"It's certainly good news for Medicare beneficiaries who have been essentially shut out of the market for GLP-1s for weight loss if they wanted to use insurance coverage. However, it is a temporary program. It is not a permanent change in Medicare coverage," said Juliette Cubanski, Vice President and Director of Medicare Policy at KFF.
If the program is not extended, beneficiaries who rely on the medications may have to pay higher out-of-pocket prices or discontinue treatment beginning in January 2028, which experts said could lead to weight regain based on current GLP-1 therapies, the Post reported.
Credit: AI generated image
Heart failure (HF) remains a major global health challenge, affecting more than 64 million adults worldwide.
To improve how the condition is prevented, diagnosed and managed, leading cardiovascular organizations, including the American Heart Association (AHA) and the American College of Cardiology (ACC), have released the "Second Universal Definition of Heart Failure."
The updated definition addresses changes in disease manifestations, diagnostic strategies and the understanding of heart failure's underlying biology. It also aims to establish a unified framework for clinicians, researchers, health systems and policymakers worldwide.
Published on behalf of the ACC, AHA, European Society of Cardiology (ESC) and World Heart Federation (WHF), in collaboration with the Heart Failure Society of America (HFSA), the Heart Failure Association (HFA) of the ESC and the Japanese Heart Failure Society (JHFS), the document updates the First Universal Definition of Heart Failure, released in 2021. It has been published simultaneously in Circulation, Journal of the American College of Cardiology (JACC), European Heart Journal and Global Heart.
The prevalence of heart failure continues to rise due to ageing populations and increasing rates of obesity, Type 2 diabetes and high blood pressure.
To better address this growing burden, the new framework introduces several important changes.
The revised definition provides a common framework for clinicians, researchers, health systems and policymakers worldwide, helping standardize diagnosis, strengthen research and support more personalized care.
The consensus document will also serve as the foundation for the upcoming American Heart Association/American College of Cardiology Heart Failure Guideline, expected to be published in late 2027.
"Heart failure remains a major challenge that continues to grow globally, and inconsistencies in how it is defined have limited progress in research and treatment. This updated definition provides a clearer, more consistent framework to help clinicians identify risk earlier and guide more personalized treatment approaches that can help improve patient outcomes worldwide," said Mary Norine Walsh, co-chair of the consensus document.
"The new framework recognizes that heart failure is not a static condition. By focusing on stages of disease, underlying causes and disease trajectories—including improvement, remission and recovery—we can better tailor care and advance prevention efforts," she added.
Credit: iStock
Amid concerns over the ongoing Ebola outbreak in neighboring Democratic Republic of Congo, Sudan has declared a new cholera outbreak, World Health Organization (WHO) Director-General Tedros Adhanom Ghebreyesus announced.
The outbreak has been reported in West Kordofan state.
As of June 20, Sudan's State Ministry of Health had reported 838 suspected cholera cases, seven confirmed cases and 117 deaths.
Conflict Hampering Response
"The outbreak is unfolding amid the continued disruption of health services caused by conflict. Population displacement is making access to essential health care even more difficult. At the same time, insecurity and access constraints continue to delay the deployment of response teams and delivery of medical supplies and humanitarian assistance," Tedros said.
He added that WHO is coordinating the response with partners by scaling up cholera treatment centers and oral rehydration points, delivering cholera kits, installing handwashing stations, training chlorinators, hygiene promoters and health workers, and supporting community health education.
Also Read: Ebola Outbreak Spreads To Fourth Province In DR Congo As Cases Rise To 1,274
Since the conflict began in 2023, Sudan has declared three waves of cholera outbreaks, with the most recent before this one occurring in January 2025 in White Nile State.
The latest announcement comes less than four months after Sudan declared the end of a cholera outbreak that began in July 2024. That outbreak spread across all 18 states, infected more than 124,000 people and claimed 3,573 lives.
According to the health ministry, the outbreak was largely linked to contaminated drinking water after the city's water supply facility was damaged in an attack by paramilitary forces.
Read More: WHO Warns of 70% Risk of Ebola Spread to South Sudan
The combination of conflict, displacement, damaged infrastructure and recurring disease outbreaks has placed millions at risk, with children under five among the most vulnerable.
According to the UNICEF, Sudan's healthcare system is also on the verge of collapse, leaving millions of children at greater risk of infectious diseases. Continued displacement has forced families into overcrowded settlements with limited access to clean water, sanitation and healthcare, creating ideal conditions for cholera and other waterborne diseases to spread.
The outbreaks have been intensified by multiple factors. The war has displaced millions, forcing many into camps with poor sanitation. Health centers, schools and water facilities have been damaged or repurposed as shelters.
Seasonal rains and flooding have further contaminated water sources, accelerating disease transmission.
According to the Centers for Disease Control and Prevention (CDC), it is caused by the bacterium Vibrio cholerae. This can be transmitted through drinking water or eating food that contains the bacteria. While most people who get cholera don't get sick, it can cause life-threatening diarrhea and vomiting.
CDC notes that each year, 1.3 to 4 million people around the world get cholera. Among them, 21,000 to 143,000 people die.
The common symptoms include:
People who live in areas with unsafe drinking water, poor sanitation, and inadequate hygiene are at the highest risk of getting cholera. The disease can spread quickly in areas where sewage and drinking water are not adequately treated. It can also live in brackish water, which is slightly salty, or in coastal water. Thus, eating raw shellfish can also cause cholera.
© 2024 Bennett, Coleman & Company Limited